Bortezomib plus standard therapy for diffuse large B-cell lymphoma

  • Davies A & al.
  • Lancet Oncol
  • 1 Apr 2019

  • curated by Dawn O'Shea
  • UK Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

The randomised evaluation of molecular-guided therapy for diffuse large B-cell lymphoma with bortezomib (REMoDL-B) trial has found no evidence that adding bortezomib to standard therapy improves outcomes in patients with diffuse germinal centre or activated B cell lymphoma.

For the study, published in the Lancet Oncology, participants were recruited from 107 cancer centres in the United Kingdom (n=94) and Switzerland (n=13).

Patients initially received one 21-day cycle of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) intravenously on day 1, and oral prednisolone on days 1-5. During this time, gene-expression profiling was carried out. Patients were then randomly assigned to continue R-CHOP alone or with bortezomib (RB-CHOP) on days 1 and 8 for cycles two to six.

At a median follow-up of 29.7 months, there was no evidence for a difference in 30-month progression-free survival (PFS) in the combined germinal centre and activated B-cell population between R-CHOP and RB-CHOP (70.1% vs 74.3%; HR, 0.86; 95% CI, 0.65-1.13; P=.28).

The most common grade ≥3 adverse event was haematological toxicity, reported in 39.8 per cent of patients given R-CHOP and 42.1 per cent of those given RB-CHOP.

Grade 3 or worse neuropathy occurred in 3.8 per cent patients given RB-CHOP versus 1.8 per cent given R-CHOP. Serious adverse events occurred in 42.5 per cent patients given R-CHOP and 50.2 per cent given RB-CHOP. There were five treatment-related deaths with R-CHOP and four with RB-CHOP.

Although the trial did not show any PFS benefit with the addition of bortezomib, it does show the feasibility of molecular phenotyping in a large multicentre study of rapidly progressive tumours and shown that the addition of bortezomib does not affect treatment outcomes in most patients with diffuse large B-cell lymphoma.